Bioequivalence of 5 Tablets of 100 mg Versus 2 Tablets of 250 mg TF3 of Tepotinib
Clinical trial NCT04204902 · COMPLETED
Trial details
- NCT number
- NCT04204902
- Sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2019-10-17
- Primary completion
- 2019-12-16
- Enrollment
- 18
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.